1. Coronary Microvascular Dysfunction in Patients with Non-Obstructive Coronary Arteries: Current Gaps and Future Directions

   • Islam Y. Elgendy
   • Lina Ya’Qoub
   • Carl J. Pepine

   Leading Article 29 January 2022 Pages: 241 - 250

   

2. Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder

   • Elizabeth M. Burnette
   • Steven J. Nieto
   • Lara A. Ray

   Review Article Open access 08 February 2022 Pages: 251 - 274

3. Pharmacologic Management of Persistent Pain in Cancer Survivors

   • Paul Glare
   • Karin Aubrey
   • Sarah Overton

   Review Article Open access 17 February 2022 Pages: 275 - 291

4. Statins and Gliomas: A Systematic Review of the Preclinical Studies and Meta-Analysis of the Clinical Literature

   • Luis F. Rendon
   • Ishaan A. Tewarie
   • Rania A. Mekary

   Systematic Review 05 February 2022 Pages: 293 - 310

   

5. Association of Metformin with the Mortality and Incidence of Cardiovascular Events in Patients with Pre-existing Cardiovascular Diseases

   • Tian Li
   • Rui Providencia
   • Heng Ma

   Original Research Article 15 January 2022 Pages: 311 - 322

   

6. Ocrelizumab: A Review in Multiple Sclerosis

   • Yvette N. Lamb

   Adis Drug Evaluation 22 February 2022 Pages: 323 - 334

   

7. Maribavir: First Approval

   • Connie Kang

   AdisInsight Report 11 February 2022 Pages: 335 - 340

   

8. Efgartigimod: First Approval

   • Young-A Heo

   AdisInsight Report Open access 18 February 2022 Pages: 341 - 348

   

9. Comment on: “Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence”

   • Mario Gennaro Mazza
   • Benedetta Vai
   • Raffaella Zanardi

   Letter to the Editor 12 February 2022 Pages: 349 - 351

10. Authors’ Reply to Mazza et al.: “Fluvoxamine for the Early Treatment of SARS‑CoV‑2 Infection: A Review of Current Evidence”

    • Eric J. Lenze
    • Angela M. Reiersen
    • Shelley N. Facente

    Letter to the Editor 12 February 2022 Pages: 353 - 354

11. Correction to: Ocular Toxicity of Targeted Anticancer Agents

    • Blake H. Fortes
    • Prashant D. Tailor
    • Lauren A. Dalvin

    Correction 15 February 2022 Pages: 355 - 355